In a deal potentially worth up to US$474 M, The Medicines Company (TMC) has acquired Rempex Pharmaceuticals to gain antibiotic programmes in varying stages of development that target three of the most common Gram-negative infections among seriously ill hospitalised patients. Rempex’s assets complement oritavancin, a semi-synthetic glycopeptide antibiotic for the treatment of acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria that TMC expects to file for regulatory approval in the US and Europe in late 2013 and the first quarter of 2014, respectively.